600530.SH
ST交昂
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 3.61
−2.43%Year over year
Reported trailing growth
- Revenue
- -4.2%
- EBITDA
- —
- EBIT
- -60.8%
- EPS
- -84.5%
- Free cash flow
- -1.7%
- Operating cash flow
- -2.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -5.9%
- EBITDA
- +176.5%
- EBIT
- -65.0%
- Net income
- -88.5%
- EPS
- -88.5%
- Free cash flow
- -34.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026